The current study provides evidence that upfront LT for advanced HCC (T3–T4) is a viable treatment option with comparable post-transplant outcomes in carefully selected patients (AFP < 600 ng/mL, no macrovascular on imaging). Here, AFP is linked to hepatocellular carcinoma.